Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Jacobson

Showing results (1141-1150 of 1,226) with videos related to

Pageof 123
Sort By:
Journal of Viral Hepatitis|August 7, 2012
Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3S Pianko, S Zeuzem, W-L Chuang, et al.
The Journal of Infectious Diseases|May 28, 2014
Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infectionNetanya G Sandler, Xinyan Zhang, Ronald J Bosch, et al.
Drug and Alcohol Dependence|November 4, 2022
Alcohol consumption upon direct-acting antiviral therapy for hepatitis C among persons with human immunodeficiency virus in the United StatesPo-Hung Chen, Karine Yenokyan, Anthony T Fojo, et al.
Hepatology (Baltimore, Md.)|October 15, 2014
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virusEric M Yoshida, Mark S Sulkowski, Edward J Gane, et al.
Scientific Reports|January 22, 2026
Genomic risk prediction of type 2 diabetes in people living with and without HIVNicole D Armstrong, Vinodh Srinivasasainagendra, Lavanya Pilla, et al.
Gastroenterology|May 26, 2012
Factors that predict response of patients with hepatitis C virus infection to boceprevirFred Poordad, Jean-Pierre Bronowicki, Stuart C Gordon, et al.
Scientific Reports|November 21, 2019
Novel gRNA design pipeline to develop broad-spectrum CRISPR/Cas9 gRNAs for safe targeting of the HIV-1 quasispecies in patientsNeil T Sullivan, Will Dampier, Cheng-Han Chung, et al.
Hepatology Communications|April 13, 2026
Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studiesStuart C Gordon, Alejandra Villamil, Ira M Jacobson, et al.
Academic Pediatrics|August 11, 2023
Adapting Behavioral Treatments for Primary Care Using a Theory-Based Framework: The Case of Adolescent Eating DisordersJocelyn Lebow, Leslie Sim, Sarah Redmond, et al.
Lancet (London, England)|August 10, 2010
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trialPaul Y Kwo, Eric J Lawitz, Jonathan McCone, et al.
Pageof 123

Showing results (1141-1150 of 1,226) with videos related to

Sort By:
Pageof 123
Journal of Viral Hepatitis|August 7, 2012
Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3S Pianko, S Zeuzem, W-L Chuang, et al.
The Journal of Infectious Diseases|May 28, 2014
Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infectionNetanya G Sandler, Xinyan Zhang, Ronald J Bosch, et al.
Drug and Alcohol Dependence|November 4, 2022
Alcohol consumption upon direct-acting antiviral therapy for hepatitis C among persons with human immunodeficiency virus in the United StatesPo-Hung Chen, Karine Yenokyan, Anthony T Fojo, et al.
Hepatology (Baltimore, Md.)|October 15, 2014
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virusEric M Yoshida, Mark S Sulkowski, Edward J Gane, et al.
Scientific Reports|January 22, 2026
Genomic risk prediction of type 2 diabetes in people living with and without HIVNicole D Armstrong, Vinodh Srinivasasainagendra, Lavanya Pilla, et al.
Gastroenterology|May 26, 2012
Factors that predict response of patients with hepatitis C virus infection to boceprevirFred Poordad, Jean-Pierre Bronowicki, Stuart C Gordon, et al.
Scientific Reports|November 21, 2019
Novel gRNA design pipeline to develop broad-spectrum CRISPR/Cas9 gRNAs for safe targeting of the HIV-1 quasispecies in patientsNeil T Sullivan, Will Dampier, Cheng-Han Chung, et al.
Hepatology Communications|April 13, 2026
Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studiesStuart C Gordon, Alejandra Villamil, Ira M Jacobson, et al.
Academic Pediatrics|August 11, 2023
Adapting Behavioral Treatments for Primary Care Using a Theory-Based Framework: The Case of Adolescent Eating DisordersJocelyn Lebow, Leslie Sim, Sarah Redmond, et al.
Lancet (London, England)|August 10, 2010
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trialPaul Y Kwo, Eric J Lawitz, Jonathan McCone, et al.
Pageof 123